Swipe for more

• April 20, 2026

  First-of-its-Kind Health Economic Analysis Shows Early Use of Fast Diagnostics in Sepsis Care Could Save Thousands of Lives and Reduce Health System Costs Across G7 Countries

  bioMérieux, a world leader in in vitro diagnostics, announces the publication of a multi-country health economic analysis assessing the impact of deploying fast identification and antimicrobial susceptibility testing (ID/AST) early in the care pathway for patients with bloodstream infections at high-risk of sepsis.

  Read more
  

• April 09, 2026

  bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing

  bioMérieux, a world leader in the field of in vitro diagnostics, announces the launch of BIOFIRE® SPOTFIRE® for pharmaceutical industries, where this innovative molecular testing system is designed to transform quality control. Building on the proven success of the BIOFIRE® FILMARRAY® platform, already adopted by leading global pharmaceutical companies, BIOFIRE® SPOTFIRE® introduces a simple, small and smart approach to mycoplasma detection, helping biopharmaceutical manufacturers strengthen quality control, accelerate decision-making, and protect patients.

  Read more
  

• April 07, 2026

  Global Agreement Announced at G7 One Health Summit to Accelerate Access to Diagnostics and Responses to Rising Health Threats

  A coalition of more than 20 international partners announced the Global One Health Diagnostics Access Compact (GO-Dx) during the G7 One Health Summit in Lyon, France. This new initiative serves as a catalyst for international leaders across different sectors to advance progress toward expanding diagnostics access, enabling early detection and better surveillance, and improving response against existing and emerging threats across human, animal, and environmental health. By aligning efforts, this group aims to strengthen global preparedness through science based One Health solutions.

  Read more